MedPath

NGM Bio Licenses NGM313 to KdT Ventures for Rare Disease Development

  • KdT Ventures is launching a new biotech startup to develop NGM313, an antibody drug licensed from NGM Biopharmaceuticals, for an unspecified rare disease.
  • NGM313, which activates proteins involved in metabolism, previously underwent Phase 2 trials for diabetes and MASH but was returned by Merck due to efficacy thresholds.
  • KdT plans to initiate a Phase 2 trial for NGM313 in a non-metabolic disease, leveraging its favorable tolerability profile demonstrated in over 300 volunteers.
  • NGM Bio will receive an equity stake, an upfront payment, and potential milestone payments up to $608 million, plus royalties on future sales.
KdT Ventures has licensed NGM313 from NGM Biopharmaceuticals to form a new biotechnology startup focused on developing the drug for an unspecified rare disease. The deal, announced Thursday, grants KdT's new venture worldwide rights to NGM313, an experimental antibody drug. NGM Bio will receive an equity stake in the new company, an upfront cash payment, and potential milestone payments up to $608 million, as well as royalties on future sales.
NGM313, an antibody drug that activates a cluster of proteins involved in metabolism, was previously investigated for diabetes and metabolic dysfunction-associated steatohepatitis (MASH). Merck & Co. had licensed the drug in 2019 but returned the rights in 2023 after it did not meet their effectiveness criteria in a Phase 2 trial. Despite this, NGM and KdT highlight that NGM313 has been studied in over 300 volunteers, demonstrating proof of mechanism and a favorable tolerability profile.

Revival of NGM313

The licensing agreement marks a new chapter for NGM313. Cain McClary, KdT’s founder and managing partner, stated, "Our partnership with NGM Bio to advance NGM313 into clinical development for an important and chronically underserved patient population reflects KdT’s commitment to backing transformative science that meaningfully impacts patients' lives." A Phase 2 trial is anticipated to commence next year, focusing on a non-metabolic disease.

NGM Bio's Strategic Shift

For NGM Bio, this deal represents a strategic move after facing challenges with other drug candidates. Following failures in mid-stage trials for MASH and geographic atrophy, the company underwent restructuring, including layoffs. David Woodhouse, NGM Bio CEO, expressed enthusiasm for NGM313's future under KdT's leadership: "We’re excited for NGM313’s next chapter under the stewardship of KdT’s new venture."
Additional details regarding the new startup are expected to be disclosed in the coming months, according to McClary.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

GlycoNex Initiates Phase 3 Trial for Denosumab Biosimilar SPD8 in Osteoporosis

GlycoNex has dosed the first patient in a Phase 3 clinical trial for SPD8, a biosimilar of denosumab, targeting osteoporosis treatment.

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.

Dimerix's Phase 3 Trial of DMX-200 for FSGS Completes Part 2 Recruitment, Interim Analysis Expected in August 2025

Dimerix has completed the randomization of the first 144 patients in its ACTION3 Phase 3 trial of DMX-200 for Focal Segmental Glomerulosclerosis (FSGS).

Mito Fund Invests in Khondrion to Advance Sonlicromanol for Primary Mitochondrial Disease

The Mito Fund has invested in Khondrion to support the Phase III development of sonlicromanol, a drug candidate for primary mitochondrial disease (PMD).

Merck Expands Oncology Pipeline with $588M Acquisition of LaNova's Bispecific Antibody LM-299

Merck is acquiring global rights to LaNova Medicines' LM-299, a bispecific antibody targeting PD-1 and VEGF, for $588 million, with potential milestone payments up to $2.7 billion.

Adenine Base Editing Shows Promise in X-Linked Chronic Granulomatous Disease Trial

Researchers utilized adenine base editors to correct disease-causing mutations in stem cells from X-CGD patients, showing high efficiency and minimal off-target effects.

Neurizon Therapeutics Repurposes Monepantel for MND Treatment in Healey ALS Platform Trial

Neurizon Therapeutics (formerly PharmAust) is repurposing monepantel, an existing animal drug, for the treatment of motor neuron disease (MND).

NeOnc Technologies Pursues Direct Listing with Intranasal Glioblastoma Therapy

NeOnc Technologies is pursuing a direct listing after withdrawing its IPO plans, aiming to fund development of NEO100, an intranasal drug for glioblastoma.

Gilgamesh Pharmaceuticals Receives $14 Million NIDA Grant for Cardiac-Safe Ibogaine Analog to Treat Opioid Use Disorder

Gilgamesh Pharmaceuticals secured a $14 million grant from the National Institute on Drug Abuse (NIDA) to advance GM-3009, a novel ibogaine analog, for opioid use disorder (OUD).

Oleolive Receives NCI Grant to Study Propentofylline for Glioblastoma Treatment

Oleolive, Inc. has been awarded a $400,000 STTR grant from the National Cancer Institute to investigate propentofylline's potential in glioblastoma treatment.

Reference News

[1]
A venture firm breathes new life into an old NGM drug | BioPharma Dive
biopharmadive.com · Dec 19, 2024

KdT Ventures launches a biotech startup with worldwide rights to NGM313, an experimental drug from NGM Biopharmaceutical...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy